Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT - 3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

ConclusionsMonotherapy with sunitinib does not have clinical activity in patients with mCRC withFLT-3 amplification and should not be prescribed for off-label use. Other treatments should be considered for these patients, including treatments offered in clinical trials.Clinical Trial registrationNCT02693535 (26 February 2016).

http://link.springer.com/10.1007/s11523-020-00752-8

Source: Targeted Oncology - October 17, 2020 Category: Cancer & Oncology Source Type: research